/TPTX

TPTX Stock - Turning Point Therapeutics, Inc.

Q: What is the analyst price target for TPTX?

Analyst price target information is not currently available for TPTX.

Q: What is TPTX's market cap?

Market capitalization information is not currently available for TPTX.

Healthcare|Biotechnology|NASDAQ

$75.49+0.12%

+$0.09 (+0.12%) • Aug 15

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-2.5%upside

Target: $73.60

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TPTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.19

52W High$N/A

52W Low$N/A

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$30.83M	$25.00M	N/A	N/A	N/A
Gross Profit	$30.83M	$25	N/A	N/A	N/A
Gross Margin	100.0%	0.0%	N/A	N/A	N/A
Operating Income	$-236,551,000	$-161,836,000	$-77,724,000	$-25,640,000	$-16,729,000
Net Income	$-236,551,000	$-157,292,000	$-72,131,000	$-24,785,000	$-16,593,000
Net Margin	-767.3%	-629.2%	N/A	N/A	N/A
EPS	$-5.79	$-3.85	$-2.99	$-1.66	$-1.11

Company Overview

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$58

Average Target

↓ 23.2% Downside

Now

$58

Low

$58

Average

$58

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 20th 2022	BofA Securities	Initiation	Buy	$58

Earnings History & Surprises

TPTX

Beat Rate

36%

Last 14 quarters

Avg Surprise

-50.2%

EPS vs Estimate

Beats / Misses

5/9

Last 12 quarters

Latest EPS

$-2.48

Q3 2022

EPS Surprise History

Q4 20

+22.2%

$-0.42vs$-0.54

Q1 21

-10.9%

$-1.02vs$-0.92

Q2 21

-19.7%

$-0.73vs$-0.61

Q3 21

+5.8%

$-1.14vs$-1.21

Q4 21

-5.5%

$-1.34vs$-1.27

Q1 22

-13.7%

$-1.58vs$-1.39

Q2 22

+0.7%

$-1.50vs$-1.51

Q3 22

-45.9%

$-2.48vs$-1.70

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2022	Aug 8, 2022	$-1.70	$-2.48	-45.9%	✗ MISS
Q2 2022	May 10, 2022	$-1.51	$-1.50	+0.7%	✓ BEAT
Q1 2022	Feb 28, 2022	$-1.39	$-1.58	-13.7%	✗ MISS
Q4 2021	Nov 9, 2021	$-1.27	$-1.34	-5.5%	✗ MISS
Q3 2021	Aug 9, 2021	$-1.21	$-1.14	+5.8%	✓ BEAT
Q2 2021	May 5, 2021	$-0.61	$-0.73	-19.7%	✗ MISS
Q1 2021	Mar 1, 2021	$-0.92	$-1.02	-10.9%	✗ MISS
Q4 2020	Nov 12, 2020	$-0.54	$-0.42	+22.2%	✓ BEAT
Q3 2020	Aug 10, 2020	$-0.89	$-0.82	+7.9%	✓ BEAT
Q2 2020	May 12, 2020	$-0.66	$-1.69	-156.1%	✗ MISS
Q1 2020	Mar 16, 2020	$-0.64	$-0.58	+9.4%	✓ BEAT
Q4 2019	Nov 4, 2019	$-0.55	$-0.63	-14.5%	✗ MISS
Q3 2019	Aug 6, 2019	$-0.65	$-0.70	-7.7%	✗ MISS
Q2 2019	May 31, 2019	$-0.69	$-3.97	-475.4%	✗ MISS
Q4 2018	Dec 31, 2018	—	$-0.32	—	—
Q3 2018	Sep 30, 2018	—	$-0.40	—	—
Q2 2018	Jun 30, 2018	—	$-0.34	—	—
Q1 2018	Mar 31, 2018	—	$-0.32	—	—

Frequently Asked Questions about TPTX

What is TPTX's current stock price?

Turning Point Therapeutics, Inc. (TPTX) is currently trading at $75.49 per share. The stock has moved +0.12% today.

What is the analyst price target for TPTX?

The average analyst price target for TPTX is $73.60, based on 1 analyst.

What sector is Turning Point Therapeutics, Inc. in?

Turning Point Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is TPTX's market cap?

Turning Point Therapeutics, Inc. has a market capitalization of N/A, making it a small-cap company.

Does TPTX pay dividends?

No, Turning Point Therapeutics, Inc. does not currently pay a dividend to shareholders.